📊 CLRB Key Takeaways
Investment Thesis
Cellectar Biosciences is a pre-revenue pharmaceutical company with severe operational losses (-$23M operating income) and negative free cash flow (-$23.1M) that will deplete its $13.2M cash position within months at current burn rate. The company demonstrates no revenue generation capability, negative profitability metrics across all measures (ROE: -255%, ROA: -145%), and faces an existential liquidity crisis despite manageable debt levels.
CLRB Strengths
- Low debt burden with debt-to-equity ratio of 0.04x reducing financial distress risk
- Adequate short-term liquidity with current ratio of 2.96x and quick ratio of 2.96x
- Net income loss improved 51.1% year-over-year indicating reduced burn trajectory
CLRB Risks
- No revenue generation with operating losses of $23M annually indicating failed commercialization or product pipeline
- Critical cash runway of approximately 6 months at current $23.1M quarterly operating burn rate
- Severe negative returns on assets (-145.5%) and equity (-255.2%) demonstrating value destruction and inefficient capital deployment
- Zero insider buying activity suggests management lacks confidence in turnaround prospects
- Pre-revenue stage with no clear path to profitability or cash flow positivity in near term
Key Metrics to Watch
- Monthly operating cash burn rate and cash runway to depletion
- Revenue generation milestones or clinical trial outcomes validating product viability
- Capital raise activities and dilution impact from necessary financing
- Operating expense reduction initiatives and pathway to profitability
CLRB Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 2.96x current ratio provides a solid financial cushion.
CLRB Profitability Ratios
CLRB vs Healthcare Sector
How Cellectar Biosciences, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
CLRB Balance Sheet & Liquidity
CLRB 5-Year Financial Trend
5-Year Trend Summary: Cellectar Biosciences, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-41.89 indicates the company is currently unprofitable.
CLRB Growth Metrics (YoY)
CLRB Capital Allocation
CLRB SEC Filings
Access official SEC EDGAR filings for Cellectar Biosciences, Inc. (CIK: 0001279704)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CLRB
What is the AI rating for CLRB?
Cellectar Biosciences, Inc. (CLRB) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are CLRB's key strengths?
Low debt burden with debt-to-equity ratio of 0.04x reducing financial distress risk. Adequate short-term liquidity with current ratio of 2.96x and quick ratio of 2.96x.
What are the risks of investing in CLRB?
No revenue generation with operating losses of $23M annually indicating failed commercialization or product pipeline. Critical cash runway of approximately 6 months at current $23.1M quarterly operating burn rate.
What is CLRB's revenue and growth?
Cellectar Biosciences, Inc. reported revenue of N/A.
Does CLRB pay dividends?
Cellectar Biosciences, Inc. does not currently pay dividends.
Where can I find CLRB SEC filings?
Official SEC filings for Cellectar Biosciences, Inc. (CIK: 0001279704) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CLRB's EPS?
Cellectar Biosciences, Inc. has a diluted EPS of $-8.35.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.